XNCR
Price:
$25.01
Market Cap:
$1.75B
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat m...[Read more]
Industry
Biotechnology
IPO Date
2013-12-03
Stock Exchange
NASDAQ
Ticker
XNCR
According to Xencor, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.81B. This represents a change of 36.53% compared to the average of 1.32B of the last 4 quarters.
The mean historical Enterprise Value of Xencor, Inc. over the last ten years is 1.44B. The current 1.81B Enterprise Value has changed 12.49% with respect to the historical average. Over the past ten years (40 quarters), XNCR's Enterprise Value was at its highest in in the June 2019 quarter at 2.46B. The Enterprise Value was at its lowest in in the March 2015 quarter at 406.39M.
Average
1.44B
Median
1.44B
Minimum
448.86M
Maximum
2.34B
Discovering the peaks and valleys of Xencor, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.16%
Maximum Annual Enterprise Value = 2.34B
Minimum Annual Increase = -30.17%
Minimum Annual Enterprise Value = 448.86M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.31B | -15.71% |
2022 | 1.56B | -30.17% |
2021 | 2.23B | -4.76% |
2020 | 2.34B | 23.09% |
2019 | 1.90B | -0.66% |
2018 | 1.92B | 89.88% |
2017 | 1.01B | -5.78% |
2016 | 1.07B | 92.11% |
2015 | 557.81M | 24.27% |
2014 | 448.86M | 115.16% |
The current Enterprise Value of Xencor, Inc. (XNCR) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
1.70B
5-year avg
1.87B
10-year avg
1.44B
Xencor, Inc.’s Enterprise Value is less than Edgewise Therapeutics, Inc. (3.01B), greater than Keros Therapeutics, Inc. (1.75B), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Mineralys Therapeutics, Inc. (523.81M), greater than Erasca, Inc. (747.42M), greater than Kura Oncology, Inc. (807.00M), less than Protagonist Therapeutics, Inc. (2.65B), less than Merus N.V. (2.68B), greater than Replimune Group, Inc. (984.10M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than IDEAYA Biosciences, Inc. (1.93B), greater than AnaptysBio, Inc. (502.56M), greater than MeiraGTx Holdings plc (427.31M), greater than Homology Medicines, Inc. (-103303255.00), less than Nuvalent, Inc. (6.38B), less than DICE Therapeutics, Inc. (1.82B), less than Arcellx, Inc. (4.79B), less than Vaxcyte, Inc. (10.01B), greater than Viridian Therapeutics, Inc. (1.42B), greater than Larimar Therapeutics, Inc. (363.34M), greater than Syndax Pharmaceuticals, Inc. (1.24B), greater than Sutro Biopharma, Inc. (57.26M),
Company | Enterprise Value | Market cap |
---|---|---|
3.01B | $3.05B | |
1.75B | $2.27B | |
439.72M | $521.60M | |
523.81M | $621.09M | |
747.42M | $763.36M | |
807.00M | $839.85M | |
2.65B | $2.77B | |
2.68B | $3.11B | |
984.10M | $1.02B | |
8.24B | $8.19B | |
1.93B | $2.32B | |
502.56M | $677.65M | |
427.31M | $463.45M | |
-103303255.00 | $3.02M | |
6.38B | $6.75B | |
1.82B | $2.27B | |
4.79B | $4.89B | |
10.01B | $11.04B | |
1.42B | $1.60B | |
363.34M | $393.05M | |
1.24B | $1.37B | |
57.26M | $206.97M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xencor, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Xencor, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Xencor, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Xencor, Inc. (XNCR)?
What is the 3-year average Enterprise Value for Xencor, Inc. (XNCR)?
What is the 5-year average Enterprise Value for Xencor, Inc. (XNCR)?
How does the current Enterprise Value for Xencor, Inc. (XNCR) compare to its historical average?